Small dense LDL-3 (sdLDL-3) represents a progressively smaller and more dangerous LDL particle subfraction. As particles decrease in size through the sdLDL series, they become more atherogenic — more capable of entering and being retained within the arterial wall, where they trigger inflammation and plaque formation.
Elevation of sdLDL-3 and beyond (sdLDL-4 through 7) is associated with the most significant cardiovascular risk in the small dense LDL series. These particles are a particularly strong predictor of risk in individuals whose total LDL appears acceptable — a phenomenon sometimes referred to as the 'LDL paradox', where individuals with standard LDL levels continue to have heart attacks because their particle pattern is atherogenic.
FAQs
How does sdLDL-3 compare to sdLDL-1 in risk?
sdLDL-3 is smaller and denser than sdLDL-1, making it more atherogenic. Atherogenicity increases progressively from sdLDL-1 (least) to sdLDL-7 (most) in the small dense LDL series.
Can I have elevated sdLDL-3 with normal LDL?
Yes. This is the clinical value of subfraction testing. Standard LDL can appear normal while the particle distribution is heavily weighted toward small dense, highly atherogenic particles.
How quickly can sdLDL-3 improve?
Significant improvement can occur within 8-12 weeks of dietary changes targeting carbohydrate reduction and triglyceride lowering.
Is this test available routinely?
sdLDL subfraction analysis is specialised testing, not part of standard lipid panels, available through advanced cardiovascular risk assessment services.
